LONDON, 25 July 2008 - Lawyers from the London office of Morrison & Foerster MNP are advising long term client Acambis plc (“Acambis”), a London main market listed vaccines company, on the terms of the recommended cash offer for the entire issued and to be issued share capital of Acambis by Sanofi Pasteur Holding (“Sanofi Pasteur”).

The acquisition is being implemented by a Scheme of Arrangement and under the terms of the Proposals, each Shareholder will receive 190 pence in cash for each Share held at the Scheme Record Time.  The Proposals value Acambis’ existing issued share capital at approximately £276 million.

Acambis is a leading developer of vaccines for, inter alia, smallpox, C. difficile and various other diseases with significant unmet medical needs.  The company recently was awarded a further US government contract (worth approximately US$425 million over 10 years) to produce and deliver smallpox vaccine to the US government for its national stockpile.  Acambis and Sanofi Pasteur already have existing partnerships on certain key projects to develop and market vaccines.

The Morrison & Foerster corporate team was led by corporate partner Paul Claydon and included partner Natalie Diep, senior associate James Halstead and associates Matthew Edwards and Mark O'Donnell and trainee Laetitia Bourgeix.  Partner Trevor James, associate Sonia Girgis and trainee Matthew Bennett are providing tax support.

Paul Claydon commented: “I have been advising Acambis since 1993 so my colleagues and I at Morrison & Foerster were delighted to assist Acambis with this sale.”

Slaughter & May are advising Sanofi Pasteur (William Underhill, David Watkins and Susannah Macknay).  Goldman Sachs International acted as financial advisers to Acambis, and JPMorgan Cazenove and Piper Jaffray are joint corporate brokers.  Morgan Stanley is advising Sanofi Pastuer.